Zobrazeno 1 - 10
of 132
pro vyhledávání: '"Mario I. Vega"'
Autor:
Mario Morales-Martínez, Mario I. Vega
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 16, p 9091 (2022)
miRNAs are non-coding RNA sequences of approximately 22 nucleotides that interact with genes by inhibiting their translation through binding to their 3′ or 5′ UTR regions. Following their discovery, the role they play in the development of variou
Externí odkaz:
https://doaj.org/article/306298046949452f9e745eb368b22fd1
Autor:
Mario Morales-Martínez, Mario I. Vega
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 4, p 2193 (2022)
Members of the Bcl-2 family are proteins that play an essential role in the regulation of apoptosis, a crucial process in development and normal physiology in multicellular organisms. The essential mechanism of this family of proteins is given by the
Externí odkaz:
https://doaj.org/article/f0df139d09644cdbae11617bd130b1e2
Autor:
Mario Morales-Martinez, Gabriel G. Vega, Natividad Neri, M. J Nambo, Isabel Alvarado, Ivonne Cuadra, M. A. Duran-Padilla, Sara Huerta-Yepez, Mario I. Vega
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The discovery and description of the role of microRNAs has become very important, specifically due to their participation in the regulation of proteins and transcription factors involved in the development of cancer. microRNA-7 (miR-7) has been descr
Externí odkaz:
https://doaj.org/article/05438ea447104fe4ab181ad65a1f052c
Autor:
Alan Lichtenstein, Joseph F. Gera, Michael E. Jung, Jihye Lee, Rogelio Hernandez-Pando, Gabriela Antonio-Andres, Sara Huerta-Yepez, Patrick Frost, Yijiang Shi, Mario I. Vega
Prior work indicates DEPTOR expression in multiple myeloma cells could be a therapeutic target. DEPTOR binds to mTOR via its PDZ domain and inhibits mTOR kinase activity. We previously identified a drug, which prevented mTOR–DEPTOR binding (NSC1264
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2059020c921a01df6787589792c87af8
https://doi.org/10.1158/1535-7163.c.6537720.v1
https://doi.org/10.1158/1535-7163.c.6537720.v1
Autor:
Alan Lichtenstein, Joseph F. Gera, Michael E. Jung, Jihye Lee, Rogelio Hernandez-Pando, Gabriela Antonio-Andres, Sara Huerta-Yepez, Patrick Frost, Yijiang Shi, Mario I. Vega
Suppl fig 6: Immunocompetent non-tumor bearing mice injected IP daily with increasing concentrations of drug 3g for 21 days followed by harvest of serum for assays of alkaline phosphatase, ALT, AST, bilirubin and BUN. Chemistry values of control mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dbe87cdf5a9d1eff4590ac68322ad8e
https://doi.org/10.1158/1535-7163.22504392
https://doi.org/10.1158/1535-7163.22504392
Autor:
Benjamin Bonavida, Ali R. Jazirehi, Kandasamy Hariharan, Nabil Hanna, Paul Chinn, Cesar R. González-Bonilla, Rogelio Hernandez-Pando, Bernardo Martinez-Miguel, Melisa Martinez-Paniagua, Sara Huerta-Yepez, Mario I. Vega
Purpose: Rituximab [chimeric anti-CD20 monoclonal antibody], alone or combined with chemotherapy, is used in the treatment of non–Hodgkin's lymphoma (NHL). Rituximab binds to CD20 and inhibits intracellular survival/growth pathways leading to chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::843096e1ec543755a15e6df26b730d79
https://doi.org/10.1158/1078-0432.c.6517765
https://doi.org/10.1158/1078-0432.c.6517765
Autor:
Benjamin Bonavida, Ali R. Jazirehi, Kandasamy Hariharan, Nabil Hanna, Paul Chinn, Cesar R. González-Bonilla, Rogelio Hernandez-Pando, Bernardo Martinez-Miguel, Melisa Martinez-Paniagua, Sara Huerta-Yepez, Mario I. Vega
Supplementary Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1213ac1010b5e7a3bb42993e5ae6b89c
https://doi.org/10.1158/1078-0432.22440436
https://doi.org/10.1158/1078-0432.22440436
Publikováno v:
Leukemia & Lymphoma. 62:1422-1431
Kruppel-like factor 4 (KLF4) is a member of the KLF transcription factor family containing zinc-fingers, and is involved in the regulation of apoptosis, proliferation and differentiation of B cells and B-cell malignancies. KLF4 can act like an oncoge
Publikováno v:
Aging (Albany NY)
Deptor is a protein that interacts with mTOR and that belongs to the mTORC1 and mTORC2 complexes. Deptor is capable of inhibiting the kinase activity of mTOR. It is well known that the mTOR pathway is involved in various signaling pathways that are i
Autor:
Mario I. Vega, Gabriela Antonio-Andres, Michael E. Jung, Sara Huerta-Yepez, Yijiang Shi, Jihye Lee, Patrick Frost, Rogelio Hernández-Pando, Joseph Gera, Alan Lichtenstein
Publikováno v:
Molecular Cancer Therapeutics. 18:1822-1831
Prior work indicates DEPTOR expression in multiple myeloma cells could be a therapeutic target. DEPTOR binds to mTOR via its PDZ domain and inhibits mTOR kinase activity. We previously identified a drug, which prevented mTOR–DEPTOR binding (NSC1264